New York, New York 10029

  • Hodgkins Lymphoma

Purpose:

The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.


Study summary:

The current FDA-approved timing for plerixafor is approximately 11 hours prior to apheresis. This is a logistical problem, since plerixafor should be administered by a health care provider, given the risk of hypotension with administration. The primary purpose of this study is, in autologous donors with non-Hodgkins lymphoma and multiple myeloma undergoing hematopoietic progenitor cell mobilization with plerixafor and G-CSF, to determine whether the dosing interval can be increased to 16 hours prior to apheresis. Patients will be admitted to a special clinical research center on the 4th day of G-CSF administration, where the peripheral blood CD34+ count will be measured every 2 hours after plerixafor administration at 5 pm until 9 AM the following day, at which time apheresis will commence. The hypothesis is that plerixafor administration 16 hours prior to apheresis is as safe and effective as plerixafor administration at 11 hours prior to apheresis.


Criteria:

Inclusion Criteria: 1. Autologous donors age 18 to 75 years with NHL or MM scheduled to undergo peripheral blood stem cell collection as part of standard clinical care. Biopsy-confirmed diagnosis of NHL or MM is to have been done prior to the first mobilization. 2. In first or second CR or PR 3. ECOG performance status of 0 or 1 4. WBC count greater than 2.5 x 10e9/1 5. Absolute PMN count greater than 1.5 x 10e9/1 6. PLT count greater than 100 x 10e9/1 7. Serum creatinine less than or equal to 2.2 mg/dl 8. SGOT, SGPT, and total bilirubin less than 2.5 X upper limit of normal (ULN) 9. Cardiac and pulmonary status sufficient to undergo apheresis and transplantation 10. Negative for HIV 11. 4 weeks since last cycle of chemotherapy. (Rituximab, thalidomide, dexamethasone, and bortezomib are not considered chemotherapy for the purpose of the study) 12. Patients of childbearing potential agree to use an approved form of contraception 13. Recovered from all acute toxic effects of prior chemotherapy Exclusion Criteria: 1. Comorbid condition which renders patient, in view of the investigators, at high risk of treatment complications 2. Failed previous stem cell collections or collection attempts 3. Less than 6 weeks of carmustine prior to the 1st dose of G-CSF 4. Received GM-CSF or pegfilgrastim within 3 weeks prior to the 1st dose of G-CSF for mobilization 5. Received G-CSF within 14 days prior to the 1st dose of G-CSF for mobilization 6. Active CNS involvement 7. Active brain metastases or carcinomatous meningitis 8. Bone marrow involvement greater than 20 percent 9. Received radiation therapy to the pelvis 10. Post-transplant chemotherapy and/or radiation therapy below the diaphragm is anticipated 11. Received prior radio-immunotherapy with Zevalin or Bexxar 12. Fever (temperature greater than 38 C/100.4 F) 13. Received bone-seeking radionuclides (e.g., holmium) 14. A residual acute medical condition resulting from prior chemotherapy 15. Active brain metastases or myelomatous meningitis 16. Received thalidomide, dexamethasone and/or Velcade within 7 days prior to the first dose of G-CSF 17. Received Revlimid within 3 weeks prior to the first dose of G-CSF 18. Received greater than 6 cycles of Revlimid 19. Positive pregnancy test or lactating 20. Active infection requiring antibiotic treatment 21. Abnormal ECG with clinically significant rhythm disturbance (ventricular arrhythmias), or other conduction abnormality in the last year that in the opinion of the investigator warrants exclusion of the subject from the trial. 22. Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the mobilization phase. 23. Patients whose apheresis product will be further selected and purified. 24. Prior autologous or allogeneic transplant.


NCT ID:

NCT01042717


Primary Contact:

Principal Investigator
Patricia A Shi, MD
Mount Sinai School of Medicine


Backup Contact:

N/A


Location Contact:

New York, New York 10029
United States

Patricia A Shi, MD
Phone: 212-241-9237
Email: patricia.shi@mssm.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: December 08, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.